Yumanity Therapeutics - YMTX Competitors

Yumanity Therapeutics (NASDAQ:YMTX) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, community ranking, dividends, institutional ownership, risk and earnings.

Does the MarketBeat Community prefer YMTX or ELDN?

Eledon Pharmaceuticals received 4 more outperform votes than Yumanity Therapeutics when rated by MarketBeat users. However, 70.00% of users gave Yumanity Therapeutics an outperform vote while only 64.29% of users gave Eledon Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Yumanity Therapeutics	Outperform Votes 14 70.00%	Underperform Votes 6 30.00%
Eledon Pharmaceuticals	Outperform Votes 18 64.29%	Underperform Votes 10 35.71%

Is YMTX or ELDN more profitable?

Eledon Pharmaceuticals has a net margin of 0.00% compared to Yumanity Therapeutics' net margin of -660.61%. Eledon Pharmaceuticals' return on equity of -25.14% beat Yumanity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yumanity Therapeutics	-660.61%	-263.34%	-107.08%
Eledon Pharmaceuticals	N/A	-25.14%	-24.13%

Which has more risk & volatility, YMTX or ELDN?

Yumanity Therapeutics has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500.

Do analysts rate YMTX or ELDN?

Eledon Pharmaceuticals has a consensus target price of $22.00, suggesting a potential upside of 746.15%. Given Eledon Pharmaceuticals' higher probable upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than Yumanity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yumanity Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Eledon Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has better valuation & earnings, YMTX or ELDN?

Eledon Pharmaceuticals has lower revenue, but higher earnings than Yumanity Therapeutics. Yumanity Therapeutics is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yumanity Therapeutics	$4.84 million	7.13	-$39.50 million	-$3.00	-1.06
Eledon Pharmaceuticals	N/A	N/A	-$34.51 million	-$2.66	-0.98

Does the media refer more to YMTX or ELDN?

In the previous week, Eledon Pharmaceuticals had 3 more articles in the media than Yumanity Therapeutics. MarketBeat recorded 3 mentions for Eledon Pharmaceuticals and 0 mentions for Yumanity Therapeutics. Eledon Pharmaceuticals' average media sentiment score of 0.22 beat Yumanity Therapeutics' score of 0.00 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Yumanity Therapeutics	Neutral
Eledon Pharmaceuticals	Neutral

Do insiders and institutionals have more ownership in YMTX or ELDN?

25.1% of Yumanity Therapeutics shares are held by institutional investors. Comparatively, 45.6% of Eledon Pharmaceuticals shares are held by institutional investors. 12.5% of Yumanity Therapeutics shares are held by insiders. Comparatively, 13.8% of Eledon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Eledon Pharmaceuticals beats Yumanity Therapeutics on 14 of the 16 factors compared between the two stocks.